ADLM 2026 to Highlight Diabetes Milestones, Space Diagnostics, and Cancer Biomarkers

ANAHEIM, CALIF. — From July 26–30, the brightest minds in clinical laboratory medicine will gather in Anaheim for ADLM 2026, a meeting poised to spotlight research that turns biomarkers into actionable care. Organized by the Association for Diagnostics & Laboratory Medicine (ADLM), the program blends translational science with practical diagnostics—spanning diabetes, brain disease, infectious risk, cancer detection, and even health monitoring beyond Earth.

The opening plenary features Dr. David M. Nathan, whose decades of work established hemoglobin A1c as the clinical gold standard for monitoring long-term glycemic control. Nathan also helped uncover how glucagon-like peptide-1 physiology lowers glucose, a mechanistic foundation for modern incretin-based therapies that have transformed the treatment landscape for diabetes and obesity.

Space medicine takes center stage next with Dr. Kathleen McMonigal, director of NASA Johnson Space Center Clinical Laboratory. She will explain how zero- and microgravity environments drive physiological shifts such as bone demineralization and fluid redistribution. The talk will emphasize the need for compact, possibly continuous monitoring systems, aiming for point-of-care capabilities that could function like a real-world “tricorder” for astronaut health.

A third plenary addresses the biological bridge between Down syndrome and Alzheimer’s disease. Dr. Elizabeth Head has spent more than 25 years investigating why individuals with trisomy 21 face elevated Alzheimer’s risk, and how chromosome-linked dosage effects may accelerate pathogenic pathways. Her research aims to identify intervention targets that could slow disease progression, with implications for broader aging populations.

Cancer screening innovation follows through the lens of Dr. Leeya Pinder, who will discuss cervical cancer prevention strategies that expand access to HPV testing. Self-collection methods can broaden screening coverage, while emerging low-cost approaches such as thermal ablation and emerging artificial intelligence tools aim to improve accuracy and deployment in resource-limited settings.

In the closing plenary, Dr. Arun Wiita will describe how mass spectrometry can drive biomarker discovery for blood cancers and support immune-based therapy development. By profiling unique cell-surface proteins, his team integrates chemical biology, high-resolution analytical workflows, and computational methods to identify candidates that are both diagnostic and therapeutically relevant.

Across these sessions, ADLM 2026 will connect laboratory methodology to clinical outcomes, underscoring how precision measurements can guide decisions in real time. With thousands of collaborators and a large Clinical Lab Expo featuring diagnostic technologies from automation to AI, the meeting is set to generate ideas that extend far beyond the conference hall.

This year’s plenaries reflect a common theme: better tests, better biomarker targets, and better pathways from discovery to patient impact.